📰 Imux News
Page 2 - Imux News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Imux. Real-time updates on events, politics, business and more.
July 21, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 2,170,000 shares, a growth of 6.9% from the June 15th total of 2,030,000 shares. Based on an average daily volume of 1,040,000 shares, the […]
June 27, 2023
Whether you love them or hate them, penny stocks are contentious. These tickers, which trade for less than $5 per share, have earned a reputation on Wall Street for their divisive nature, leaving investors struggling to find common ground on the matter. The appeal is clear. For the same price as one share of a more well-known company, investors can snap up hundreds of shares of a penny stock. What’s more, the fact that even minor share price appreciation can translate to irresistible perc...
June 5, 2023
Vivo Capital LLC acquired a new stake in shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 632,184 shares of the company’s stock, valued at approximately $833,000. Vivo Capital LLC owned approximately […]
May 22, 2023
StockNews.com assumed coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the stock. Separately, Wedbush reiterated an outperform rating and issued a $5.00 price objective on shares of Immunic in a report on Tuesday, January 31st. One investment […]
May 21, 2023
StockNews.com started coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report report published on Thursday morning. The firm issued a sell rating on the stock. Separately, Wedbush restated an outperform rating and set a $5.00 target price on shares of Immunic in a report on Tuesday, January 31st. One investment analyst […]
May 17, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 […]
May 16, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) was the recipient of a large decrease in short interest during the month of April. As of April 30th, there was short interest totalling 3,650,000 shares, a decrease of 14.7% from the April 15th total of 4,280,000 shares. Based on an average trading volume of 1,310,000 shares, the short-interest […]
May 16, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 3,650,000 shares, a decline of 14.7% from the April 15th total of 4,280,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is presently […]
May 11, 2023
Immunic (NASDAQ:IMUX – Get Rating) and ObsEva (NASDAQ:OBSV – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation. Institutional and Insider Ownership 60.7% of Immunic shares are held by […]
May 10, 2023
Immunic (NASDAQ:IMUX – Get Rating) is set to release its earnings data before the market opens on Thursday, May 11th. Analysts expect Immunic to post earnings of ($0.54) per share for the quarter. Immunic (NASDAQ:IMUX – Get Rating) last issued its earnings results on Thursday, February 23rd. The company reported ($1.63) earnings per share (EPS) […]